Why Investors Need to Take Advantage of These 2 Medical Stocks Now

HCA Healthcare has a +0.37% Zacks Earnings ESP, based on a $6.77 most accurate EPS estimate versus $6.74 consensus, ahead of its October 27, 2026 report. ResMed has a +0.11% ESP, with a $2.68 estimate versus $2.67 consensus, ahead of its October 29 report; both are rated Zacks Rank #3 (Hold), so potential earnings beats are not assured. Zacks says stocks combining positive ESP with a rank of #3 or better posted positive surprises 70% of the time in its analysis and averaged 28.3% annual returns in a 10-year backtest.

Analysis

The signal is too small to underwrite a pre-earnings position: the cited estimate gaps are only +0.37% for HCA and +0.11% for ResMed, while both carry Hold ratings. A small positive estimate revision is not equivalent to positive earnings momentum, and a reported beat may already be reflected in expectations. The article’s historical hit rate and return figures are vendor backtest claims; without methodology, sample construction, and transaction-cost details, they are not an investable edge.

Near term, the main exposure is event volatility, not a demonstrated change in fundamentals. For HCA, focus on admission volumes, payer mix, labor expense, and guidance; read-throughs could affect Tenet Healthcare and Universal Health Services, but the article provides no operating evidence supporting a sector call. For ResMed, monitor device demand, gross-margin commentary, and channel/inventory signals; Philips is a relevant competitive reference, not a confirmed beneficiary or loser from this item.

Over 1–3 months, guidance and estimate revisions matter more than the headline beat. Over 6–18 months, HCA’s earnings sensitivity to labor and reimbursement, and ResMed’s demand durability and potential substitution effects, are the structural questions. The contrarian point: the article sells a screening rule, not company-specific information. Treat the ESP as a weak catalyst indicator, not a thesis. Verify current consensus, revision breadth, options-implied move, and reported operating metrics before taking risk.

Key Decisions for Investors

• No pre-earnings directional trade based solely on these ESP figures. With reports imminent, compare each stock’s options-implied move with historical post-earnings moves and confirm the estimates are current; avoid paying event premium unless the expected edge is clear.
• After HCA reports, consider a relative-value position only if operating data diverges: favor HCA versus hospital peers if admissions and guidance are strong without labor-cost deterioration; abandon the thesis if guidance or labor expense contradicts it. No peer trade is supported by the article alone.
• For ResMed, wait for results and commentary on demand, margins, and channel inventory before positioning. A beat without stronger forward guidance or estimate revisions is not sufficient confirmation; monitor Philips as a competitive read-through, not a proxy position.
• Reassess within days of each report and over the next 1–3 months as revisions arrive. Falsifiers are a negative guidance revision, weakening operating metrics, or no follow-through in estimates after a headline beat; absent those data, keep both on watch rather than force a trade.